Hong Kong-based Insilico Medicine is partnering with U.S. firm Human Longevity to develop AI foundation models capable of predicting diseases like cancer decades before symptoms appear. This collaboration aims to advance early disease detection.

Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as cancer – decades before clinical symptoms appear. The partnership was announced as the global longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and...